C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries

Sean M. O'Neill, Dina K. Olympia, Todd E. Fox, J. Tony Brown, Thomas C. Stover, Kristy L. Houck, Ronald Wilson, Peter Waybill, Mark Kozak, Steven W. Levison, Norbert Weber, Linda M. Karavodin, Mark Kester

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Drug eluting stents have recently been associated with the increased risk of adverse thrombogenic events and/or late luminal loss, which is highly associated with incomplete re-endothelialization. The increased risks behoove the design of alternative delivery modalities and/or drugs that do not compromise the re-endotheliaization process. The objective of the present study is to elucidate the biological mechanism(s) by which non-stent-based delivery modalities for the anti-proliferative lipid metabolite, C6-ceramide, could lead to a reduction in arterial injury after angioplasty. Results: Immunohistochemical studies in rabbit and porcine models suggest that C 6-ceramide-coated balloon catheters limit arterial stenosis without inhibiting endothelial wound healing responses. Specifically, C 6-ceramide-coated balloon catheters reduce internal elastica injury with a corresponding reduction in medial fracture length in a 28-day porcine coronary artery stretch model. In addition, C6-ceramide decreases the formation of the fibrin matrix to possibly augment the subsequent wound healing response. We hypothesized that differential metabolism of exogenous ceramide by coronary endothelial and smooth muscle cells could explain the apparent discrepancy between the anti-proliferative actions of ceramide and the pro-wound healing responses of ceramide. Human coronary artery endothelial cells (HCAEC), in contrast to human coronary artery smooth muscle cells (HCASMC), preferentially express ceramide kinase and form ceramide-1-phosphate, which promotes endothelial cell survival. Conclusion: Differential metabolism of ceramide between HCASMC and HCAEC offers a mechanism by which ceramide preferentially limits smooth muscle cell growth, in the presence of active wound healing. The combinatorial ability of ceramide to limit vascular smooth muscle proliferation and promote re-endothelialization, offers the potential for C 6-ceramide-coated catheters to serve as adjuncts to stent-based modalities or as a stand-alone treatment.

Original languageEnglish (US)
Pages (from-to)200-210
Number of pages11
JournalVascular Disease Prevention
Volume5
Issue number3
DOIs
StatePublished - Aug 1 2008

Fingerprint

Ceramides
Catheters
Arteries
Coronary Vessels
Wound Healing
Smooth Muscle Myocytes
Endothelial Cells
Swine
Drug-Eluting Stents
Rubber
Wounds and Injuries
Fibrin
Vascular Smooth Muscle
Angioplasty
Stents
N-caproylsphingosine
Cell Survival
Pathologic Constriction
Rabbits
Lipids

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Cardiology and Cardiovascular Medicine

Cite this

O'Neill, S. M., Olympia, D. K., Fox, T. E., Brown, J. T., Stover, T. C., Houck, K. L., ... Kester, M. (2008). C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries. Vascular Disease Prevention, 5(3), 200-210. https://doi.org/10.2174/156727008785133809
O'Neill, Sean M. ; Olympia, Dina K. ; Fox, Todd E. ; Brown, J. Tony ; Stover, Thomas C. ; Houck, Kristy L. ; Wilson, Ronald ; Waybill, Peter ; Kozak, Mark ; Levison, Steven W. ; Weber, Norbert ; Karavodin, Linda M. ; Kester, Mark. / C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries. In: Vascular Disease Prevention. 2008 ; Vol. 5, No. 3. pp. 200-210.
@article{58c4dbb838b54c6c963df17ffb398a87,
title = "C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries",
abstract = "Objective: Drug eluting stents have recently been associated with the increased risk of adverse thrombogenic events and/or late luminal loss, which is highly associated with incomplete re-endothelialization. The increased risks behoove the design of alternative delivery modalities and/or drugs that do not compromise the re-endotheliaization process. The objective of the present study is to elucidate the biological mechanism(s) by which non-stent-based delivery modalities for the anti-proliferative lipid metabolite, C6-ceramide, could lead to a reduction in arterial injury after angioplasty. Results: Immunohistochemical studies in rabbit and porcine models suggest that C 6-ceramide-coated balloon catheters limit arterial stenosis without inhibiting endothelial wound healing responses. Specifically, C 6-ceramide-coated balloon catheters reduce internal elastica injury with a corresponding reduction in medial fracture length in a 28-day porcine coronary artery stretch model. In addition, C6-ceramide decreases the formation of the fibrin matrix to possibly augment the subsequent wound healing response. We hypothesized that differential metabolism of exogenous ceramide by coronary endothelial and smooth muscle cells could explain the apparent discrepancy between the anti-proliferative actions of ceramide and the pro-wound healing responses of ceramide. Human coronary artery endothelial cells (HCAEC), in contrast to human coronary artery smooth muscle cells (HCASMC), preferentially express ceramide kinase and form ceramide-1-phosphate, which promotes endothelial cell survival. Conclusion: Differential metabolism of ceramide between HCASMC and HCAEC offers a mechanism by which ceramide preferentially limits smooth muscle cell growth, in the presence of active wound healing. The combinatorial ability of ceramide to limit vascular smooth muscle proliferation and promote re-endothelialization, offers the potential for C 6-ceramide-coated catheters to serve as adjuncts to stent-based modalities or as a stand-alone treatment.",
author = "O'Neill, {Sean M.} and Olympia, {Dina K.} and Fox, {Todd E.} and Brown, {J. Tony} and Stover, {Thomas C.} and Houck, {Kristy L.} and Ronald Wilson and Peter Waybill and Mark Kozak and Levison, {Steven W.} and Norbert Weber and Karavodin, {Linda M.} and Mark Kester",
year = "2008",
month = "8",
day = "1",
doi = "10.2174/156727008785133809",
language = "English (US)",
volume = "5",
pages = "200--210",
journal = "Vascular Disease Prevention",
issn = "1567-2700",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

O'Neill, SM, Olympia, DK, Fox, TE, Brown, JT, Stover, TC, Houck, KL, Wilson, R, Waybill, P, Kozak, M, Levison, SW, Weber, N, Karavodin, LM & Kester, M 2008, 'C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries', Vascular Disease Prevention, vol. 5, no. 3, pp. 200-210. https://doi.org/10.2174/156727008785133809

C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries. / O'Neill, Sean M.; Olympia, Dina K.; Fox, Todd E.; Brown, J. Tony; Stover, Thomas C.; Houck, Kristy L.; Wilson, Ronald; Waybill, Peter; Kozak, Mark; Levison, Steven W.; Weber, Norbert; Karavodin, Linda M.; Kester, Mark.

In: Vascular Disease Prevention, Vol. 5, No. 3, 01.08.2008, p. 200-210.

Research output: Contribution to journalArticle

TY - JOUR

T1 - C6-ceramide-coated catheters promote re-endothelialization of stretch-injured arteries

AU - O'Neill, Sean M.

AU - Olympia, Dina K.

AU - Fox, Todd E.

AU - Brown, J. Tony

AU - Stover, Thomas C.

AU - Houck, Kristy L.

AU - Wilson, Ronald

AU - Waybill, Peter

AU - Kozak, Mark

AU - Levison, Steven W.

AU - Weber, Norbert

AU - Karavodin, Linda M.

AU - Kester, Mark

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Objective: Drug eluting stents have recently been associated with the increased risk of adverse thrombogenic events and/or late luminal loss, which is highly associated with incomplete re-endothelialization. The increased risks behoove the design of alternative delivery modalities and/or drugs that do not compromise the re-endotheliaization process. The objective of the present study is to elucidate the biological mechanism(s) by which non-stent-based delivery modalities for the anti-proliferative lipid metabolite, C6-ceramide, could lead to a reduction in arterial injury after angioplasty. Results: Immunohistochemical studies in rabbit and porcine models suggest that C 6-ceramide-coated balloon catheters limit arterial stenosis without inhibiting endothelial wound healing responses. Specifically, C 6-ceramide-coated balloon catheters reduce internal elastica injury with a corresponding reduction in medial fracture length in a 28-day porcine coronary artery stretch model. In addition, C6-ceramide decreases the formation of the fibrin matrix to possibly augment the subsequent wound healing response. We hypothesized that differential metabolism of exogenous ceramide by coronary endothelial and smooth muscle cells could explain the apparent discrepancy between the anti-proliferative actions of ceramide and the pro-wound healing responses of ceramide. Human coronary artery endothelial cells (HCAEC), in contrast to human coronary artery smooth muscle cells (HCASMC), preferentially express ceramide kinase and form ceramide-1-phosphate, which promotes endothelial cell survival. Conclusion: Differential metabolism of ceramide between HCASMC and HCAEC offers a mechanism by which ceramide preferentially limits smooth muscle cell growth, in the presence of active wound healing. The combinatorial ability of ceramide to limit vascular smooth muscle proliferation and promote re-endothelialization, offers the potential for C 6-ceramide-coated catheters to serve as adjuncts to stent-based modalities or as a stand-alone treatment.

AB - Objective: Drug eluting stents have recently been associated with the increased risk of adverse thrombogenic events and/or late luminal loss, which is highly associated with incomplete re-endothelialization. The increased risks behoove the design of alternative delivery modalities and/or drugs that do not compromise the re-endotheliaization process. The objective of the present study is to elucidate the biological mechanism(s) by which non-stent-based delivery modalities for the anti-proliferative lipid metabolite, C6-ceramide, could lead to a reduction in arterial injury after angioplasty. Results: Immunohistochemical studies in rabbit and porcine models suggest that C 6-ceramide-coated balloon catheters limit arterial stenosis without inhibiting endothelial wound healing responses. Specifically, C 6-ceramide-coated balloon catheters reduce internal elastica injury with a corresponding reduction in medial fracture length in a 28-day porcine coronary artery stretch model. In addition, C6-ceramide decreases the formation of the fibrin matrix to possibly augment the subsequent wound healing response. We hypothesized that differential metabolism of exogenous ceramide by coronary endothelial and smooth muscle cells could explain the apparent discrepancy between the anti-proliferative actions of ceramide and the pro-wound healing responses of ceramide. Human coronary artery endothelial cells (HCAEC), in contrast to human coronary artery smooth muscle cells (HCASMC), preferentially express ceramide kinase and form ceramide-1-phosphate, which promotes endothelial cell survival. Conclusion: Differential metabolism of ceramide between HCASMC and HCAEC offers a mechanism by which ceramide preferentially limits smooth muscle cell growth, in the presence of active wound healing. The combinatorial ability of ceramide to limit vascular smooth muscle proliferation and promote re-endothelialization, offers the potential for C 6-ceramide-coated catheters to serve as adjuncts to stent-based modalities or as a stand-alone treatment.

UR - http://www.scopus.com/inward/record.url?scp=48749124126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749124126&partnerID=8YFLogxK

U2 - 10.2174/156727008785133809

DO - 10.2174/156727008785133809

M3 - Article

C2 - 19946459

AN - SCOPUS:48749124126

VL - 5

SP - 200

EP - 210

JO - Vascular Disease Prevention

JF - Vascular Disease Prevention

SN - 1567-2700

IS - 3

ER -